These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27422051)

  • 61. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant.
    García-Herola A; Prieto M; Pascual S; Berenguer M; López-Viedma B; Mir J; Vilchez JJ; Berenguer J
    Liver Transpl Surg; 1999 May; 5(3):246-8. PubMed ID: 10226117
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
    Coutinho MC; Cortez-Dias N; Cantinho G; Conceição I; Oliveira A; Bordalo e Sá A; Gonçalves S; Almeida AG; de Carvalho M; Diogo AN
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):627-36. PubMed ID: 23833285
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tafamidis.
    Said G; Grippon S; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Mar; 11(3):185-6. PubMed ID: 22378262
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
    Schwarzman AL; Gregori L; Vitek MP; Lyubski S; Strittmatter WJ; Enghilde JJ; Bhasin R; Silverman J; Weisgraber KH; Coyle PK
    Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8368-72. PubMed ID: 8078889
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The presence of S-sulfonated transthyretin in commercial human serum albumin solutions: Potential contribution to neuropathy.
    Rael LT; Bar-Or R; Banton KL; Mains CW; Madayag RM; Marshall GT; Allen Tanner II; Waxman M; Acuna DL; Bar-Or D
    Clin Chim Acta; 2019 Dec; 499():70-74. PubMed ID: 31479652
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy.
    Nedkova-Hristova V; Baliellas C; González-Costello J; Lladó L; González-Vilatarsana E; Vélez-Santamaría V; Casasnovas C
    Transpl Int; 2022; 35():10454. PubMed ID: 35497887
    [No Abstract]   [Full Text] [Related]  

  • 67. Metabolism of normal and Met30 transthyretin.
    Hanes D; Zech LA; Murrell J; Benson MD
    Adv Food Nutr Res; 1996; 40():149-55. PubMed ID: 8858811
    [No Abstract]   [Full Text] [Related]  

  • 68. Amyloid neuropathy: a peculiar form of peripheral neuropathy.
    Wang AK
    Arch Neurol; 2001 May; 58(5):822-3. PubMed ID: 11346380
    [No Abstract]   [Full Text] [Related]  

  • 69. Oxidative Stress: Neuropathy, Excitability, and Neurodegeneration.
    Latini A; Pereira PJS; Couture R; Campos MM; Talbot S
    Oxid Med Cell Longev; 2019; 2019():2715326. PubMed ID: 30723534
    [No Abstract]   [Full Text] [Related]  

  • 70. An elderly male with tingly legs and a heavy heart: Persisting with the diagnosis!
    Kharadi M; Harsha SV; Gopalakrishnan G; Karthick GA; Raj V; Kannan S
    Ann Indian Acad Neurol; 2016; 19(4):444-447. PubMed ID: 27994350
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical management of amyloid cardiomyopathy.
    Kim MM; Kolseth CM; Carlson D; Masri A
    Heart Fail Rev; 2022 Sep; 27(5):1549-1557. PubMed ID: 34471997
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nerve biopsy: Current indications and decision tools.
    Nathani D; Spies J; Barnett MH; Pollard J; Wang MX; Sommer C; Kiernan MC
    Muscle Nerve; 2021 Aug; 64(2):125-139. PubMed ID: 33629393
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amyloid Proteins and Peripheral Neuropathy.
    Asiri MMH; Engelsman S; Eijkelkamp N; Höppener JWM
    Cells; 2020 Jun; 9(6):. PubMed ID: 32604774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy.
    González-Duarte A; Conceição I; Amass L; Botteman MF; Carter JA; Stewart M
    Neurol Ther; 2020 Jun; 9(1):135-149. PubMed ID: 32232748
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.
    Palma JA; Gonzalez-Duarte A; Kaufmann H
    Clin Auton Res; 2019 Sep; 29(Suppl 1):33-44. PubMed ID: 31452021
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
    Gonzalez-Duarte A
    Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transthyretin familial amyloid polyneuropathy: an update.
    Plante-Bordeneuve V
    J Neurol; 2018 Apr; 265(4):976-983. PubMed ID: 29249054
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.